AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $55.72 and last traded at $52.3660, with a volume of 238397 shares changing hands. The stock had previously closed at $51.52.
Analyst Ratings Changes
Several analysts recently commented on ATRC shares. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. BTIG Research raised their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. Finally, Needham & Company LLC boosted their price objective on AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.
Get Our Latest Analysis on AtriCure
AtriCure Stock Down 1.3%
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current year.
Insider Buying and Selling at AtriCure
In other AtriCure news, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director directly owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This represents a 13.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Salvatore Privitera sold 7,763 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total value of $407,557.50. Following the completion of the transaction, the insider directly owned 150,921 shares in the company, valued at $7,923,352.50. This trade represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 61,379 shares of company stock valued at $2,557,552. Corporate insiders own 4.00% of the company’s stock.
Institutional Investors Weigh In On AtriCure
Institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure during the 2nd quarter worth approximately $37,000. Harbor Investment Advisory LLC acquired a new stake in shares of AtriCure during the second quarter worth $40,000. Allworth Financial LP acquired a new stake in shares of AtriCure in the 2nd quarter worth $43,000. Integrated Wealth Concepts LLC purchased a new stake in AtriCure in the 2nd quarter valued at approximately $46,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Read More
- Five stocks we like better than AtriCure
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
